topic

442-H IL-21 on/off switch CAR-T enhance anti-tumor effects by epigenetic and transcriptional regulation
Hyungseok Seo

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1792; DOI: 10.1136/jitc-2023-SITC2023.0442-H
442-I Enhancing TCR-T responses and overcoming the tumor microenvironment by combination with a TGFβ-specific CAR
Michael R Weist, Ethan BenDavid, Melanie L Munguia, Jessica Reyes, Ximin Chen, Giulia Parisi, Jiajia Cui, Orit Foord, Jim Johnston

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1793; DOI: 10.1136/jitc-2023-SITC2023.0442-I
442-J Anti-AXL CAR-NK cell immunotherapy to target BRAF inhibitor drug-resistant and metastatic melanoma
Yanlin Yu

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1794; DOI: 10.1136/jitc-2023-SITC2023.0442-J
442-K A CAR T cell approach for treating B cell lineage cancers expressing membrane IgE
Shenyu Zhang, Brittany Fay, Zhengyu Ma

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1795; DOI: 10.1136/jitc-2023-SITC2023.0442-K
442-M Tumor targeted, adipose-derived human mast cells have anti-tumor effects in vivo after intravenous injection
Rebecca Praetzel, Jennelle Norem, Mason Conine, Caelin Smith, Samantha Vicencio, Benjamin James, Daniel Courter, Chris Kepley

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1797; DOI: 10.1136/jitc-2023-SITC2023.0442-M
442-N RNA primed SMAR-T^TM cells against multiple driver mutations, all HLA’s, designed for first line therapy
Walter Barry, Farzonai Muzaffar, Sriram Srivatsa, Ground Entrance, Ryan Campbell, Abenezer Abera, Alfred E Slanetz

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1798; DOI: 10.1136/jitc-2023-SITC2023.0442-N
442-P Characterizing human Vδ1⁺ and Vδ2⁺ γδ T cells for tumor immunotherapy development
Kok Fei Chan, Tianming Li, Simone Ostrouska, Andrew Hammet, Marc Rigau, Adam P Uldrich, Andreas Behren

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1800; DOI: 10.1136/jitc-2023-SITC2023.0442-P
442-Q CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation
Jiri Eitler, Wiebke Rackwitz, Natalie Wotschel, Venugopal Gudipati, Johannes Huppa, Paola Ortiz Montero, Laurent Boissel, Hans Klingemann, Winfried Wels, Torsten Tonn

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1801; DOI: 10.1136/jitc-2023-SITC2023.0442-Q
579-A Targeting the NANOG-CRY1 axis sensitizes immunotherapy-refractory tumors and enhances efficacy of T cell-based immunotherapy by reinvigorating the anti-tumor immunity cycle
Min Kyu Son, Se Jin Oh, Tae Woo Kim

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1802; DOI: 10.1136/jitc-2023-SITC2023.0579-A
579-B TIGIT and PD-L1 co-blockade promotes clonal expansion of non-exhausted anti-tumour CD8⁺ T cells by facilitating costimulation
Katherine Nutsch, Karl L Banta, Thomas D Wu, Charles W Tran, Stephanie Mittman, Ellen Duong, Barzin Y Nabet, Yan Qu, Namrata S Patil, Eugene Y Chiang, Ira Mellman

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1803; DOI: 10.1136/jitc-2023-SITC2023.0579-B

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages